REPH Key Statistics, Chart & Performance
The current stock price of REPH is 2.09 null. In the past month the price increased by 30.63%. In the past year, price decreased by -31.48%.
REPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.35 | 1.03T | ||
| JNJ | JOHNSON & JOHNSON | 19.82 | 495.71B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.48B | ||
| PFE | PFIZER INC | 7.9 | 143.79B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.80B | ||
| ZTS | ZOETIS INC | 20.01 | 55.90B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.8 | 23.24B | ||
| VTRS | VIATRIS INC | 5.41 | 14.51B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.21 | 11.55B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.45B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.72B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About REPH
Company Profile
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The company is headquartered in Exton, Pennsylvania and currently employs 258 full-time employees. The company went IPO on 2014-03-07. The firm is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. The company also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. The company operates in one segment. The company provides support services capabilities, which includes preparation of clinical trial supplies, specialized services for the development and Good Manufacturing Practices (GMP) of products, as well as aseptic fill/finish and lyophilization. The firm develops and/or manufactures various products, such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM and Verapamil SR. Its manufacturing and development capabilities include formulation, product development through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms.
Company Info
RECRO PHARMA INC
1 E. Uwchlan Ave, Suite 112
Exton PENNSYLVANIA 19341 US
CEO: J. David Enloe
Employees: 258
Phone: 17705348239.0
RECRO PHARMA INC / REPH FAQ
What does REPH do?
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The company is headquartered in Exton, Pennsylvania and currently employs 258 full-time employees. The company went IPO on 2014-03-07. The firm is engaged in solving formulation and manufacturing challenges for companies developing oral solid dose drug products. The company also focuses on developing sterile injectables oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles. The company operates in one segment. The company provides support services capabilities, which includes preparation of clinical trial supplies, specialized services for the development and Good Manufacturing Practices (GMP) of products, as well as aseptic fill/finish and lyophilization. The firm develops and/or manufactures various products, such as Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM and Verapamil SR. Its manufacturing and development capabilities include formulation, product development through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms.
What is the stock price of RECRO PHARMA INC today?
The current stock price of REPH is 2.09 null. The price decreased by -0.48% in the last trading session.
What is the dividend status of RECRO PHARMA INC?
REPH does not pay a dividend.
What is the ChartMill rating of RECRO PHARMA INC stock?
REPH has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the Price/Earnings (PE) ratio of RECRO PHARMA INC (REPH)?
RECRO PHARMA INC (REPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
What is the expected growth for REPH stock?
The Revenue of RECRO PHARMA INC (REPH) is expected to grow by 22.76% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
REPH Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to REPH. When comparing the yearly performance of all stocks, REPH turns out to be only a medium performer in the overall market: it outperformed 67.27% of all stocks.
REPH Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to REPH. While REPH is still in line with the averages on profitability rating, there are concerns on its financial health.
REPH Financial Highlights
Over the last trailing twelve months REPH reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 73.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -15.09% | ||
| ROA | -7.09% | ||
| ROE | N/A | ||
| Debt/Equity | 2.27 |
REPH Forecast & Estimates
9 analysts have analysed REPH and the average price target is 5.1 null. This implies a price increase of 144.02% is expected in the next year compared to the current price of 2.09.
For the next year, analysts expect an EPS growth of 5.68% and a revenue growth 22.76% for REPH